Objective: To explore the clinical efficacy of ultrasound-guided (125)I seed implantation in the treatment of delayed hepatic metastasis from colon carcinoma.
Methods: From January 2012 to December 2014, 48 patients with delayed hepatic metastasis from colon carcinoma (study group) underwent (125)I seed implantation. The clinical data and therapeutic effect in the study group were retrospectively analyzed and the therapeutic efficacy was compared with that of 59 patients with delayed hepatic metastasis from colon carcinoma (control group) who underwent ultrasound-guided radiofrequency ablation (RFA). The clinical data of these patients were analyzed retrospectively.
Results: In the 48 patients of study group, there were 13 cases of complete response (CR), 23 cases of partial response (PR), 8 cases of stable disease (SD) and 4 cases of progressive disease (PD). In the 59 patients of control group, there were 16 cases of CR, 28 cases of PR, 9 cases of SD and 6 cases of PD. The objective response rate (ORR) was 75.0% in the study group and 74.6% in the control group.The results of Ridit analysis showed that the therapeutic effect in the two groups was similar (P>0.05). The 0.5-, 1- and 2-year overall survival rates in the study group and control group were 97.9%, 83.3%, 66.7% and 96.6%, 84.8%, 69.5%, respectively, showing no significant statistical difference between the two groups (P>0.05).
Conclusion: (125)I seed implantation has positive effects in the treatment of delayed hepatic metastasis from colon carcinoma, and is of much value for clinic application.